Home Nav
Nextech Invest Logo

Thilo Schroeder

Alfred Scheidegger

Prior to joining Nextech Invest in 2012, Dr. Schroeder focused on research specializing on the development of novel cancer therapies in various roles at the University of Zurich, Switzerland, at Micromet Ltd. in Munich, Germany, (now Amgen) as well as during his studies at the University of Sydney, Australia. Dr. Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ: BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ: TCON). He holds a PhD in biochemistry from the University of Zurich, Switzerland, an MSc in biotechnology from the École de Supérieure de Biotechnologie de Strasbourg, France and a BSc in biology from the Technical University of Darmstadt, Germany. 

Mr. Schroeder is responsible for the following Nextech Invest portfolio companies:

TRACON, Peloton, Kura Oncology, ImaginAB, Blueprint

 

AACR Annual Meeting 2017

01.04. – 05.04.2017

Washington, DC, USA

  • 28.03.2017

    Tracon Pharmaceuticals announces TRC694 data presentation...

  • 27.03.2017

    Blueprint Medicines to present on BLU-285 and BLU-554...

  • 22.03.2017

    Jounce Therapeutics to present at AACR annual meeting...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close